← All trials
NCT02234934
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2015
- Primary completion
- Dec 1, 2018
- Completion date
- Dec 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- University of California, Los AngelesLead sponsor
- California Institute for Regenerative MedicineCollaborator
- University of California, Los AngelesOverall official - principal investigator
- University of California, Los AngelesReponsible party - principal investigator
- University of California, Los AngelesStudy chair
- GenethonCollaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Harvard UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.